Cohort study on COPD exacerbations in London
Relationship Between Patient Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease.
Imperial College London · NCT02755974
This study looks at what causes flare-ups in people with COPD to help understand how the disease affects their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 40 Years to 100 Years |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT02755974 on ClinicalTrials.gov |
What this trial studies
The London COPD Exacerbation Cohort aims to investigate the factors influencing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD). This observational study builds on a long-established cohort and focuses on various aspects such as exacerbation frequency, lung function, baseline therapy, inflammatory markers, health status, gene expression, and co-morbidities. By analyzing these factors, the study seeks to better understand the progression of COPD and its impact on patients' health. Participants will be phenotyped based on their individual characteristics and health metrics.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 40 years and older with a confirmed diagnosis of COPD and a specific lung function measurement.
Not a fit: Patients with asthma, bronchiectasis, or significant respiratory diseases, as well as those on immunosuppressive medications or with active cancer, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for COPD patients, enhancing their quality of life and reducing exacerbation rates.
How similar studies have performed: Other studies have shown success in understanding COPD exacerbations through similar cohort approaches, indicating that this methodology is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Forced Expiratory Volume in 1 sec (FEV1)/Forced Vital Capacity (FVC) ratio of \<0.70 * Able and willing to give informed and written consent Exclusion Criteria: * Patients with a history of asthma, bronchiectasis, carcinoma of the bronchus, or other significant respiratory disease were excluded. * Patients on Immunosuppressive medications or with active cancer * Long term steroid therapy * Age \<40 years at recruitment
Where this trial is running
London
- National Heart and Lung Institute, Imperial College — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Jadwiga Wedzicha — Imperial College London
- Study coordinator: Jadwiga A Wedzicha, MD
- Email: j.wedzicha@imperial.ac.uk
- Phone: 2075947947
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease